MaaT Pharma

Boosting Survival Through Innovative Immune Modulation

September 2026

MAAT LISTED EURONEXT

ELIGIBLE PEA PME



Disclaimer

This document has been prepared by MaaT Pharma (the "Company") and is for information and background purposes only.

While the information contained herein has been prepared in good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the fairness, accuracy, reliability or completeness of the information in this document, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers, including financial information (all such information being referred to as "Information"), and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees, affiliates, representatives or advisers take any responsibility for, or will accept any liability whether direct or indirect express or implied, contractual, tortuous, statutory or otherwise, in respect of the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising from this document.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.

The information contained in this document has not been subject to independent verification and are qualified in their entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the regulated market of Euronext in Paris, including in particular the risk factors and other information in the Company's Document d'enregistrement (Registration Document) registered by the French Autorité des marches financiers (Financial Markets Authority) (the "AMF") on October 1st, 2021 under no. I.21-0057 and its supplement on October 14, 2021 under no. I.21-0061 and in any other periodic report, which are available free of charge on the websites of the Company (https://www.maatpharma.com/) and the AMF (www.amf-france.org).

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisers concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable.

Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.

All persons accessing this document are deemed to agree to all the limitations and restrictions set out above.



Company Overview

MaaT Pharma: A Clinical-Stage Company with a Differentiated Oncology Platform

Clinical proof of concept in hemato-oncology

- ARES trial met its primary endpoint.

ARES SAT		
	61.2% Day-28 GI-ORR	**54.2%** Reported 1-year OS
CHRONOS contextualization	37.3% Day-28 GI-ORR	28.9% Day-28 GI-ORR

- PHOENIX is planned as a global randomized Phase 3 trial versus pre-specified Best Available Therapy.
- MAA process led to recommendation to conduct a RCT to overcome the limitation of a SAT (refusal of CMA) -> Proposed Phoenix RCT trial equipoise and feasibility endorsed

Multi-Assets Oncology Platform

MET-N **Standardized, donor-derived**

Xervyteg® (MaaT013): ARES trial completed

MaaT033: PHOEBUS RCT Phase 2b ongoing

MET-C **Scalable, donor-independent**

Co-cultured microbial ecosystem platform

MaaT034: IND-enabling activities progressing

Integrated European cGMP manufacturing capabilities

Potential expansion into immuno-oncology

MaaT034 **First MET-C candidate**



- **Designed for combination with immune checkpoint inhibitors in solid tumors.**

€18.1m
cash at 31 March 2026

December 2026
cash horizon under current operational assumptions

Strategic review
Exploring financing and strategic options

MET: Microbiome Ecosystem Therapy, MAA: Marketing Authorization Application; GI-ORR: gastrointestinal overall response rate; RCT: randomized controlled trial, SAT: Single-arm trial; CMA: Conditional Marketing Authorization; IND: Investigational New Drug, CMC: Chemistry, Manufacturing and Controls

Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings

STARTING POINT

Dysbiosis

- Loss of microbial **diversity**
- Increase in **pathogens**
- Reduction of **beneficial microbial metabolites**
- Associated with **multiple conditions**

Restoration of microbiota diversity + production of functional metabolites

→ **Resolution of aGvHD**

→ **Improved survival in allo-HSCT**

→ **Enhanced response to ICI**

i.e. NSCLC, Melanoma

EXPECTED BENEFITS

Xervyteg® (MaaT013)

Control of inflammation and restoration of gut integrity

Smith PM et al., Science 2013; Sun M et al., Nat Commun 2018; Ghaudier E et al., AJPGI 2004; Furusawa Y et al., Nature 2013; Arpaia N et al., Nature 2013; Mathewson ND et al., Nat Immunol 2016

MaaT033

Reduction of transplant-related complications

Jenq R et al, Biol Blood Marrow Transplant 2005; Taur Y et al, Blood J Am Soc Hematol 2014; Peled et al. NEJM 2020

MaaT034

Optimization of anti-tumor immunity

M. Vetizou et al, Science 2015; Spencer et al, Science 2021; Mager et al., Science 2020

aGvHD: acute Graft-versus-Host Disease, allo-HSCT: allogeneic hematopoietic stem cell transplant, ICI: Immune Checkpoint Inhibitors, NSCLC: Non-small cell lung cancer

Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates

gut Print

Native Ecosystem

- Xervyteg® (MaaT013)
- MaaT033

PROPRIETARY POOLING APPROACH

Xervyteg® (MaaT013) + MaaT033

Pooled microbiota → Maximized richness → Standardized (450 OTU ± 3%)

Co-cultured Ecosystem

- MaaT034
- MaaT03X

Donor stool
↓
Screening for target profile
↓
Master bank
↓
Working Bank
↓
Unlimited Co-Culture Scaling

Multistep co-culture cGMP proprietary process

MET-C product

cGMP Manufacturing Facility

- **11,000** products/year
- **1,300,000** capsules/year
- **Up to 300,000** capsules/year

Europe's Largest GMP Facility Dedicated to Microbiome Ecosystem Therapies™ powers our integrated production of a premier portfolio of native and co-cultured treatments—designed for seamless scalability

OTU: Operational Taxonomic Unit, cGMP: Current Good Manufacturing Practice

A Diversified Pipeline with Clinical-Stage Assets

Indication	Program	Indication	PRCL → Ph. 1 → Ph. 2 → Ph. 3	Current Status	Recent or Upcoming milestones
Hemato-Oncology	Xervyteg® (MaaT013) *ODD FDA/ EMA*	aGvHD	ARES completed, PHOENIX RCT Planned →	Subject to appropriate funding and regulatory clearance	Negative CHMP opinion following re-examination – September 2026
			EAP (13 countries EU/US) ongoing: +250 pts treated	Ongoing	U.S. Readiness
	MaaT033 *ODD EMA*	Allo-HSCT	PHOEBUS (Phase 2b) →	Ongoing	6 Independent DSMB Reviews since FPI LPI expected Q4 2027
Immuno-Oncology	MaaT034	Solid tumors NSCLC, melanoma	IND-enabling →	GMP batches & Regulatory Activities	**Pre-IND Meeting in Oct. 2026**

Investigator-sponsored studies are generating complementary clinical insights into the potential of microbiome modulation to overcome resistance to immune checkpoint inhibitors in solid tumors. Timing remains subject to the sponsor's discretion and the Company has no control over the study results communication timelines.*

aGvHD: acute Graft versus Host Disease; Allo-HSCT: Allogeneic Hematopoietic Stem Cell Transplantation; IST: Investigator Sponsored Trial; LPI: Last Patient In; NSCLC: Non-small cell lung cancer; ODD: Orphan Drug Designation; FPI: First Patient In; IND: Investigational New Drug; RCT: Randomized Controlled Trial; FDA: U.S. Food and Drug Administration, EMA: European Medicines Agency; EAP: Early Access Program; pts: patients; CHMP: Committee for Medicinal Products for Human Use; DSMB: Data Safety Monitoring Board

** PICASSO Trial with AP-HP, Gustave Roussy and IMMUNOLIFE Trial with Gustave Roussy, INSERM, Université Paris-Saclay, Bioaster, INRAe, IHU Méditerranée Infection (- ICI PICASSO: ipilimumab (Yervoy®) and nivolumab (Opdivo®) ; ICI IMMUNOLIFE: cemiplimab*



Xervyteg®(MaaT013) in aGvHD

Undeniable High Unmet Medical Need With No Approved Therapies

Third-line refractory aGvHD, a rare disease with high morbidity and substantial patient burden

- Prolonged hospitalization
- Profound immune suppression
- Severe infectious risk
- Multi-organ dysfunction
- Impaired QoL
- Multilayered immunosuppressive approach
- Gut microbiome dysbiosis

Advanced acute GvHD of the intestine



Acute GvHD of the skin



Treatment Paradigm in aGvHD

- 1L treatment: High-dose Corticosteroids
- 2L treatment: Ruxolitinib (approved for SR-aGvHD)
- 3L treatment: **No approved therapy** and Off label Best Available Therapies (BAT) have limited clinical benefit

BAT 3L benchmark[1]

86 days	29%	36%	20%
median OS	1-year OS	D28 ORR	D56 ORR

A clearly defined, high-value 3L population

Annual EU/U.S. patient funnel

~22,000	allo-HSCT
~11,000	1L
~5,000	2L
~3,000	3L

~3,000
addressable 3L patients (EU/US)

US: $300M[2]
EU: $70M-$95M[2]
peak annual sales[2]

A rare-disease market with a concentrated treatment pathway

aGvHD: acute Graft-versus-Host Disease; SR-aGvHD: Steroid Refractory aGvHD; OS: Overall Survival; QoL: Quality of Life. [1]CHRONOS STUD Y n=59, EU, retrospective, May 2019-Sept 2022 - Clausen et al., BMT 2026
[2] US: 1,200 patients, EU: 1,800 patients, $70M-$95M PYS, ROTW not included

Treatment with Xervyteg® (MaaT013) restores eubiosis and key microbiome functions associated with durable clinical response

Clinical data demonstrates Xervyteg® (MaaT013) engrafts and drives positive microbiome change in aGvHD patients



Percentage of total bacterial community; can only be measured from D5 after Dose 1 of Xervyteg® (MaaT013) (ARES trial; n=38)

- D28 GI Responders
- D28 GI Non- responders

Microbial richness
Butyrate producing bacteria
Production of SCFA (HERACLES study)[2]

◆ Xervyteg® (MaaT013) Administration

Preclinical and clinical data show Xervyteg® (MaaT013) modulates key mechanisms relevant to aGvHD pathophysiology

Gut barrier integrity



Xervyteg® (MaaT013) significantly increased TEER in Caco-2/THP-1 *in vitro* epithelial damage model[1]

Citrulline (marker of epithelial regeneration) in clinical responders

Immune homeostasis



Xervyteg® (MaaT013) stimulated dendritic-cell mediated amplification of regulatory T cells *in vitro*[1]

CCL25, CCL28 (markers of mucosal immune tolerance) in clinical responders

Xervyteg® (MaaT013) in blue

[1] *Laperrousaz B, et al (2026) Front Microbiol 17:1920614; 2 Malard F, et al (2023) eClinicalMedicine 62:102111*

ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day-28 GI-ORR; Responses Sustained Through Month 3

Response Rate (n=67)



Primary Endpoint Met with Significant Day-28 GI-ORR

Secondary endpoints:

- Day 28 all-organ ORR
- Durability of response (ORR at Day 56, Month 3, Duration of response)
- Overall survival
- Safety

Key Takeaways

Response is sustained through month 3

46.3% **GI-ORR** DAY 56 › **43.3%** **GI-ORR** MONTH 3

Complete Response + Very Good Partial Response account for most of the Day 28 response

*GI-ORR: gastrointestinal Overall Response Rate , ORR: Overall Response Rate, *ORR per prespecified criteria (define CR/VGPR/PR). Assessments by IRC. Population: FAS. Threshold rationale: derived from Reach 1 data – The percentages have been rounded to the nearest whole number*

ARES: Higher Observed Overall Survival vs Best Available Therapy (BAT) in 3L

CHRONOS: real world outcomes in CS- and ruxolitinib-refractory GI-aGvHD

n=59



ARES: pivotal study outcomes in CS- and ruxolitinib-refractory GI-aGvHD (n=66)

n=66



OS: Overall Survival, CS: Corticosteroids, GI-aGvHD: Gastrointestinal acute Graft-versus-Host Disease

Xervyteg® (MaaT013) **achieves a 54% 1-year OS:** Higher observed survival versus a contemporaneous real-world cohort; descriptive, non-randomized comparison

ARES and CHRONOS were not randomized or matched. Cross-study comparisons should be interpreted cautiously.

OS was analyzed among the 66 subjects who received at least 1 dose of Xervyteg® (MaaT013), as per SAP

PHOENIX: Planned Global Randomized Phase 3 Study

Trial population

PHOENIX study (n=138)

Subject to appropriate funding and regulatory clearance

Key inclusion criteria

- Adult aGvHD patients grade II to IV with lower GI involvement, with or without other organs involved
- Refractory to corticosteroids and either refractory or intolerant to ruxolitinib



Timelines *(expected)*

- H1 2027: FPI
- H1 2029: LPI
- 2030: potential BLA

Stratification:

- Baseline aGvHD grade (II *vs* III/IV)
- Geographical area (US *vs* ex-US)

Cross-over from BAT to experimental arm authorized if no response at Day 28 or loss of response after Day 28

Objective:

Compare efficacy and safety of Xervyteg® (MaaT013) vs pre-defined BAT post-corticosteroids and ruxolitinib failure

Primary endpoint (IRC):

Day 28 all-organ ORR

Key secondary (hierarchical testing) endpoints (IRC):

- GI-ORR at Day 28
- All-organ ORR at Day 56
- Duration of response

Safety endpoints:

- Incidence of AEs, SAEs, Solicited AEs, AESI
- Cumulative incidence of infections
- Incidence of serious GI complications

WHERE US | EUROPE & UK | AUS & CAN & TUR

Endpoints clinically and regulatory-compliant

BAT: Best Available Therapy; GI: gastrointestinal, ORR: overall response rate; aGvHD: acute Graft-versus-Host Disease; IRC: Independent Review Committee; R: Randomization, AE: Adverse event, SAE: Serious adverse event; AESI: Adverse event of special interest; US: United States; IRC: Independent Review Committee; AUS: Australia, CAN: Canada, TUR: Turkey; FPI: First Patient In; LPI: Last Patient In; BLA: Biologics License Application; D: Day

Early Access Program Shows an Increasing International Demand from Physicians

Number of authorizations



*Members of EU

Broad participation in the EAP has enabled real-world clinical experience with Xervyteg® (MaaT013) across multiple transplant centers.

Clinical Outcomes (Real World Evidence)

- **173 GvHD patients** analyzed as of October 2024 and presented at **EHA 2025**:
  - Efficacy (All lines) = GI-ORR at D28: **53%**; 1Y OS: **48%**
  - Efficacy (3L) = GI-ORR at D28: **57%**; 1Y OS: **51%** consistent with ARES data:
  - ARES Data = GI-ORR at D28: **61.2%**; 1y OS: **54.2%**
  - Safety = Favorable B/R ratio
- Product positioning in third-line (3L) aGvHD

Data Presented at Leading Hematology Congresses since 2020:

- ASH Annual Meeting
- EBMT Annual Meeting
- EHA Annual Meeting

EAP: Early Access Program; GI: gastrointestinal, ORR: overall response rate; D: Day, GvHD: Graft-versus-Host Disease; B/R: Benefice-Risk profile



MaaT033 in allo-HSCT

PHOEBUS (MaaT033) - Phase 2b, Randomized (1:1), Double-Blind, Placebo-Controlled Study in Allo-HSCT

PHOEBUS Trial flow chart



Design presented at congresses such as EBMT, EHA, SOHO and ASH

388 patients

59 sites

6 countries

Exp. Q4 2027 LPI

Exp. Q4 2028 Topline Results

Main Inclusion Criteria

- Subjects aged ≥ 50 years
- Allo-HSCT with a reduced-toxicity or intensity conditioning regimen.
- Patients with neutrophils > 0.5 G/L
- Patients having received broad-spectrum antibiotics within the last 90 days prior to inclusion

Endpoints

Primary endpoint: overall survival at 12 months after allo-HSCT.

Secondary endpoints:

- → Evaluation of the safety of MaaT033,
- → GvHD-free survival, GvHD-free/ relapse-free survival at M12,
- → Cumulative incidence of acute and chronic GvHD,
- → Non-relapse mortality, incidence of severe infections,
- → Quality of life.

Largest* Active, Interventional Microbiome RCT in Oncology

RCT trial designed to be pivotal, pending outcome and final regulatory interactions

Independent DSMB oversight in place since First Patient Inclusion

~ 6k patients per year EU/US

*RCT: Randomized Controlled Trial, LPI: Last Patient In, DSMB: Data Safety Monitoring Board; * To the Company's knowledge; Allo-HSCT: Allogeneic Hematopoietic Stem Cell Transplantation; GvHD: Graft-versus-Host Disease*



MaaT034: Unlocking The Full Potential of Immunotherapy Through The Microbiome

Primary Resistance to ICIs: A Major Unmet Need for Patient with Advanced Cancers

High Unmet Medical Need



Lung Cancer (NSCLC)

60% rate of relapse of ICI treated NSCLC*

416,000/Year
NSCLC patients US + EU5 (2025)

44,000
addressable patient population of unresectable advanced stages, ICI refractory



Skin Cancer (Melanoma)

50% rate of relapse of ICI treated Melanoma

210,000/year
Melanoma US + EU5 (2025)

5,000
addressable patient population of unresectable advanced stages ICI refractory

01 Approximately 19 million new cancer cases are diagnosed worldwide each year.

02 Immune Checkpoint Inhibitors (ICI) have significantly improved outcomes of patients with solid tumors, yet a **substantial unmet medical need remains.**

03 Several **combination strategies** used and investigated to improve responses to ICI, but are unsuccessful and/or associated with a **higher toxicity.**

Urgent need to develop new combination therapies to increase the response rates to current ICI while reducing toxicity.

**1L PD-1 monotherapy (KEYNOTE 024) and for 1L pembro/chemo (KEYNOTE 189) in non-squamous NSCLC*

Reck et al. N Engl J Med. 2016, Mok TSK, et al Lancet 2019, Robert C et al. N Engl J Med. 2015, Larkin J et al. N Engl J Med. 2015, Amaral T et al. Cancers. 2020,

The microbiome, a Promising Therapeutic Target in Immuno-Oncology With a Deep Biological Rationale



Almonte, Zitvogel (2025) *J Immunother Cancer* 13:e01154

Microbiome is associated with ICI response

- Microbiome diversity tracks with ICI response across solid tumors; antibiotic- and chemo-driven dysbiosis predicts non-response [1,2,3,4]

Preclinical data validates mechanism

- Stool from ICI responder patients improves ICI efficacy in mice[14,15,16]
- *In vitro* and *in vivo* data show microbes can reduce inflammation, restore barrier, and strengthen anti-tumor immunity [1,5,9,10]

Interventional studies provide POC

- POC trials with donor stool show ICI response via systemic and local immune modulation and depletion of pro-inflammatory bacteria [6,7,8,11,12,13]
- Response rates 50-80% for fecal microbiotherapy plus ICI in treatment-naïve melanoma [6,13], NSCLC [6], and mRCC [17,18]

Sources: [1] Sokol H, et al (2026) Mol. Ther. [2] Almonte AA, et al (2026) Cell Res 36:103–120; [3] Elkrief A, et al. (2024) npj Precis Oncol 8:143; [4] Zhang X et al (2026) Commun Med 6:298 ; [5] Jeong et al (2026) Cancer Immunol Res OF1-OF11; [6] Duttagupta et al. (2026) Nat Med 1-14; [7] Fernandes et al (2026) Nat Med 1-12; [8] Porcari et al (2026) Nat Med 1–9 ; [9] Robinson et al. Cancer Res 85:2219-2219; [10] Reygner et al. 2025 (SITC); [11] Davar et al., Science 2021;371:595-602; [12] Baruch et al., Science 2021;371:602-609; [13] Routy et al. (2023) Nat Med 29:2121–2132; [14] Routy et al (2018) Science 91-97; [15]Gopalakrishnan V, et al (2018) Science 97-103; [16]Matson V, et al (2018) Science 104:108; [17] Fernandes et al (2026) Nat Med 1-12; [18] Porcari et al (2026) Nat Med 1–9

Novel Microbiome Therapeutic in Immuno-Oncology Built on Clinical and Manufacturing Expertise in Microbiome Ecosystem Therapies (MET)

MET-N — STANDARDIZED, DONOR-DERIVED

Reproducible products, late-stage clinical data in hemato-oncology

61.2% Pooled-donor, high-richness MET.

D28 GI-ORR, ARES trial in 3L refractory GI-aGvHD (n=67) [1]

MET-C — CO-CULTURED, DONOR-INDEPENDENT

MaaT034: donor-independent by design

Co-cultured ecosystem tuned for tumor-agnostic use with checkpoint inhibitors — no donor-stool dependence.

Preclinical: potentiates anti-PD-1 activity and safely colonizes the GI tract.



POSTER PRESENTATIONS - PROFFERED ABSTRACTS | APRIL 21 2025

AACR 2025

Abstract 2209: MaaT034, a new co-cultured microbiome ecosystem therapy candidate, is capable to safely colonize the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and to stimulate immunity FREE

Bastien Laperrousaz; Julie Reygner; Charlotte Petitjean; Aurore Duquenoy; Cyrielle Gasc; Diane Plouchart; Sophie Declomesnil; Carole Schwintner; Nathalie Corvaïa

Check for updates

+ Author & Article Information

Cancer Res (2025) 85 (8_Supplement_1): 2209.

https://doi.org/10.1158/1538-7445.AM2025-2209

Laperrousaz et al. · Cancer Res 2025;85(8_Suppl_1):2209

Microbiome and Other Environmental Factors · 4 November 2025 · Open access Request permissions Cite this article Share

SITC 2025

1150 MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

Author affiliations · Julie Reygner [1], Charlotte Petitjean [1], Emmanuel Prestat [1], Cyrielle Gasc [1], Aurore Duquenoy [1], Sophie Declomesnil [1], Carole Schwintner [1], Nathalie Corvaia [1], Kathy D McCoy [2], Bastien Laperrousaz [1] Hide authors

Reygner et al. · J Immunother Cancer 2025;13(Suppl 2):A1316

[1] *Malard et al (2025) Blood 146:817 (Oral Presentation, 2025 ASH Conference); GI: gastrointestinal; GI-ORR: gastrointestinal overall response rate; 3L: Third line treatment*

MET-C: a Scalable and Innovative Platform for Generating Reproducible Complex Microbiotherapies

- 🧬 AI-defined microbiota features associated with ICI response
- 📈 Scalable, demand-driven manufacturing enabled by co-cultured technology
- 🎯 Consistent batches: >80% species composition similarity
- 🏭 Proprietary characterization and identity assays developed
- 🔄 CMC-focused Pre-IND meeting scheduled with the FDA for October 2026



ICI: Immune Checkpoint Inhibitors; FDA: U.S. Food and Drug Administration; AI: Artificial Intelligence; CMC: Chemistry, Manufacturing and Controls; IND: Investigational New Drug

Preclinical Data Demonstrate MaaT034 Shows Properties Associated with Microbiome Potentiation of ICI Response

MaaT034 (yellow in all figures)

Engrafts and produces immunomodulatory metabolites in germ-free mouse model





Durable engraftment (left) with enrichment of metabolite classes in germ-free mice (right; n=8/group)

Restores gut barrier integrity and reduces inflammation





Decreases pro-inflammatory cytokines and increases anti-inflammatory cytokines (left); Increased gut barrier integrity in in vitro model (right)

Activates immune response





Triggers DC-mediated T-cell priming (left) and potentiates tumor killing in melanoma cell line (right; NSCLC results comparable)

MaaT034 Enhances Anti-Tumor Efficacy of Anti-PD-1 Therapy in Germ-Free Mice Preclinical Proof of Concept



UNIVERSITY OF CALGARY
Dr. Kathy McCoy Lab

Tumor growth



Survival



*Two experiments of 5 mice/group, mean ± SEM; * p < 0.02*

MaaT034 potentiates the anti-tumor activity of anti-PD1 and improves survival *in vivo*

A Unique Innovation with a Potential Path to Clinical Validation

Built on MET-N learnings

10+ years of scientific, CMC and regulatory expertise leveraged into MET-C

1

Innovation

AI-enabled functional feature selection and proprietary co-culture technology

2

Unique & scalable

Donor-independent ecosystem delivering reproducible antitumor immune functions

3

Regulatory: FDA-first strategy

Pre-IND CMC-focused meeting planned for October 2026

4

Multiple value inflection points

First-in-Human study targeted for late 2027

5

To support the clinical development, MaaT Pharma is exploring financing opportunities from investors and strategic partnerships with pharmaceutical companies.

FDA: U.S. Food and Drug Administration; AI: Artificial Intelligence; CMC: Chemistry, Manufacturing and Controls; IND: Investigational New Drug

Upcoming Milestones

Upcoming Milestones

*** Subject to appropriate funding and regulatory clearance.**

Program	Current status	Next operational step	Potential milestone
Xervyteg® (MaaT013)/ PHOENIX	Phase 3 RCT preparation*	Funding and regulatory clearance	Potential FPI H1 2027 in the U.S. and Rest of the World
MaaT033 / PHOEBUS	Phase 2b RCT ongoing	Study execution	LPI Q4 2027; topline results Q4 2028 (exp.)
MaaT034	IND-enabling*	CMC and regulatory preparation	Pre-IND CMC-focused meeting planned for October 2026 with the FDA; Potential FPI late 2027
IO investigator-sponsored studies	Ongoing / sponsor-led	Continued follow-up	Study execution and the timing of results are controlled by the study sponsors.

RCT: randomized controlled trial; IND: Investigational New Drug, CMC: Chemistry, Manufacturing and Controls, FPI: First Patient In, LPI: Last Patient In

Corporate Social Responsibility

MaaT Pharma is a leading, late-stage clinical Company committed to advancing gut microbiome science to deliver safe, sustainable, and innovative therapies that **modulate the immune system and improve outcomes for cancer patients.**

Patients are the priority. MaaT Pharma is committed to patients and to the protection of human health by respecting the environment, valuing its employees, and ensuring good governance practices.

MaaT Pharma's core values are guided by the following four principles:

- → Innovate and raise awareness to **deliver better care,**
- → Foster employee growth within a **people-oriented ecosystem**,
- → Place **ethics and transparency** at the core of the Company's strategy,
- → Control and measure **the Company's environmental impact.**

2025 CSR indicators

Social

38 y-o is the average age of permanent employees

10 permanent employees under 30 years old (as of 12/31/25)

90% Training Plan Completion Rate

Environment

2616 tCO2e Carbon footprint

252 kWh /Employee Energy consumption per employees on site

Societal

84% of operating expenses related to R&D as a proportion of total operating expenses

299 public engagements to raise awareness of the microbiome

Governance

53% of women on the Board of Directors

53% of independents on the Board of Directors

43% of women in the Executive Committee



Thank you

MAAT
LISTED
EURONEXT

ELIGIBLE
PEA
PME